-
1
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: an update
-
Ghany M.G., Strader D.B., Thomas D.L., American Association for the Study of Liver Diseases, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
American Association for the Study of Liver, Diseases4
-
2
-
-
0030039651
-
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
-
Fattovich G., Giustina G., Favarato S., et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
-
(1996)
J Hepatol
, vol.24
, pp. 38-47
-
-
Fattovich, G.1
Giustina, G.2
Favarato, S.3
-
3
-
-
84882252475
-
Psychiatric clearance for patients started on interferon-alpha-based therapies
-
Lotrich F.E. Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry 2013, 170:592-597.
-
(2013)
Am J Psychiatry
, vol.170
, pp. 592-597
-
-
Lotrich, F.E.1
-
4
-
-
84876740954
-
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
-
Lawitz E., Lalezari J.P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, 13:401-408.
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 401-408
-
-
Lawitz, E.1
Lalezari, J.P.2
Hassanein, T.3
-
5
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson I.M., McHutchison J.G., Dusheiko G., ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
ADVANCE Study, Team4
-
6
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F., McCone J., Bacon B.R., SPRINT-2 Investigators, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
SPRINT-2, Investigators4
-
7
-
-
80055076797
-
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
-
Manns M., Reesink H., Berg T., et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011, 16:1021-1033.
-
(2011)
Antivir Ther
, vol.16
, pp. 1021-1033
-
-
Manns, M.1
Reesink, H.2
Berg, T.3
-
8
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
-
9
-
-
84871814966
-
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
-
Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
-
(2013)
N Engl J Med
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
-
10
-
-
84947614716
-
Medications to treat HCV
-
Spach DH, editor. Hepatitis C online. Accessed May 15
-
Spach DH, Kim HN. Medications to treat HCV. In: Spach DH, editor. Hepatitis C online. Available at: . Accessed May 15, 2015. http://www.hepatitisc.uw.edu/page/treatment/drugs.
-
(2015)
-
-
Spach, D.H.1
Kim, H.N.2
-
11
-
-
84964240184
-
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers
-
Giroux S., Bilimoria D., Cadilhac C., et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers. Bioorg Med Chem Lett 2015, 25:936-939.
-
(2015)
Bioorg Med Chem Lett
, vol.25
, pp. 936-939
-
-
Giroux, S.1
Bilimoria, D.2
Cadilhac, C.3
-
12
-
-
84964227488
-
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b
-
Giroux S., Bilimoria D., Cadilhac C., et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b. Bioorg Med Chem Lett 2015, 25:940-943.
-
(2015)
Bioorg Med Chem Lett
, vol.25
, pp. 940-943
-
-
Giroux, S.1
Bilimoria, D.2
Cadilhac, C.3
-
13
-
-
3042547162
-
The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach
-
Cammà C., Di Bona D., Craxì A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004, 10:2123-2130.
-
(2004)
Curr Pharm Des
, vol.10
, pp. 2123-2130
-
-
Cammà, C.1
Di Bona, D.2
Craxì, A.3
-
14
-
-
77957233758
-
Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
-
Singal A.G., Waljee A.K., Shiffman M., et al. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010, 32:969-983.
-
(2010)
Aliment Pharmacol Ther
, vol.32
, pp. 969-983
-
-
Singal, A.G.1
Waljee, A.K.2
Shiffman, M.3
-
15
-
-
84877782905
-
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
-
Chen J., Florian J., Carter W., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013, 144:1450-1455.
-
(2013)
Gastroenterology
, vol.144
, pp. 1450-1455
-
-
Chen, J.1
Florian, J.2
Carter, W.3
-
16
-
-
84931560807
-
EASL recommendations on treatment of hepatitis C 2015
-
Electronic address: easloffice@easloffice.eu
-
European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 10.1016/j.jhep.2015.03.025.
-
(2015)
J Hepatol
-
-
-
17
-
-
84928898919
-
Recommendations for testing, managing, and treating hepatitis C. 2014
-
Updated April 9, 2015. Accessed May 9
-
AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. Updated April 9, 2015. Available at: . Accessed May 9, 2015. http://hcvguidelines.org.
-
(2015)
-
-
-
18
-
-
84878976866
-
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
-
Kowdley K.V., Lawitz E., Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, 381:2100-2107.
-
(2013)
Lancet
, vol.381
, pp. 2100-2107
-
-
Kowdley, K.V.1
Lawitz, E.2
Crespo, I.3
-
19
-
-
84984953152
-
Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with metavir F0-2: COSMOS study subgroup analysis
-
Sulkowski M.S., Jacobson I.M., Ghalib R., et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with metavir F0-2: COSMOS study subgroup analysis. Gastroenterol Hepatol (N Y) 2014, 9:1-18.
-
(2014)
Gastroenterol Hepatol (N Y)
, vol.9
, pp. 1-18
-
-
Sulkowski, M.S.1
Jacobson, I.M.2
Ghalib, R.3
-
20
-
-
84911409020
-
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study
-
Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
-
(2014)
Lancet
, vol.384
, pp. 1756-1765
-
-
Lawitz, E.1
Sulkowski, M.S.2
Ghalib, R.3
-
21
-
-
84894297488
-
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection
-
Gane E.J., Stedman C.A., Hyland R.H., et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014, 146:736-743.e1.
-
(2014)
Gastroenterology
, vol.146
, pp. 736-743.e1
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
-
22
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
Afdhal N., Zeuzem S., Kwo P., ION-1 Investigators, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
-
(2014)
N Engl J Med
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
ION-1, Investigators4
-
23
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
Kowdley K.V., Gordon S.C., Reddy K.R., ION-3 Investigators, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370:1879-1888.
-
(2014)
N Engl J Med
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
ION-3, Investigators4
-
24
-
-
84925362379
-
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
-
Bourlière M., Bronowicki J.P., de Ledinghen V., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015, 15:397-404.
-
(2015)
Lancet Infect Dis
, vol.15
, pp. 397-404
-
-
Bourlière, M.1
Bronowicki, J.P.2
de Ledinghen, V.3
-
25
-
-
84899068302
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
Feld J.J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1594-1603.
-
(2014)
N Engl J Med
, vol.370
, pp. 1594-1603
-
-
Feld, J.J.1
Kowdley, K.V.2
Coakley, E.3
-
26
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
Ferenci P, Bernstein D., Lalezari J., PEARL-III Study, PEARL-IV Study, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370:1983-1992.
-
(2014)
N Engl J Med
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
-
27
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
-
(2014)
N Engl J Med
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
28
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., AI444040 Study Group, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1306218.
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
AI444040 Study, Group4
-
29
-
-
84879198467
-
1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-1, a phase III trial
-
Jacobson I., Dore G.J., Foster G.R., et al. 1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013, 58:S574.
-
(2013)
J Hepatol
, vol.58
, pp. S574
-
-
Jacobson, I.1
Dore, G.J.2
Foster, G.R.3
-
30
-
-
84879198467
-
1413 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-2, a phase III trial
-
Manns M., Marcellin P., Poordad F.P., et al. 1413 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013, 58:S568.
-
(2013)
J Hepatol
, vol.58
, pp. S568
-
-
Manns, M.1
Marcellin, P.2
Poordad, F.P.3
-
31
-
-
84933181408
-
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection: analysis of phase 3 ION trials
-
Alqahtani S.A., Afdhal N., Zeuzem S., et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection: analysis of phase 3 ION trials. Hepatology 2015, 10.1002/hep.27890.
-
(2015)
Hepatology
-
-
Alqahtani, S.A.1
Afdhal, N.2
Zeuzem, S.3
-
32
-
-
84958599246
-
A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1
-
Vienna (Austria), April 22-26
-
Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LB14. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
-
(2015)
Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
-
-
Kwo, P.1
Gitlin, N.2
Nahass, R.3
-
33
-
-
84895736477
-
SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study
-
Jacobson I.M., Ghalib R.H., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013, 58:1379A.
-
(2013)
Hepatology
, vol.58
, pp. 1379A
-
-
Jacobson, I.M.1
Ghalib, R.H.2
Rodriguez-Torres, M.3
-
34
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1316366.
-
(2014)
N Engl J Med
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
-
35
-
-
84904647749
-
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
-
Andreone P., Colombo M.G., Enejosa J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014, 147:359-365.e1.
-
(2014)
Gastroenterology
, vol.147
, pp. 359-365.e1
-
-
Andreone, P.1
Colombo, M.G.2
Enejosa, J.V.3
-
36
-
-
84899106124
-
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
Zeuzem S., Jacobson I.M., Baykai T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1604-1614. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1401561.
-
(2014)
N Engl J Med
, vol.370
, pp. 1604-1614
-
-
Zeuzem, S.1
Jacobson, I.M.2
Baykai, T.3
-
37
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
van der Meer A.J., Veldt B.J., Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.
-
(2012)
JAMA
, vol.308
, pp. 2584-2593
-
-
van der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
-
38
-
-
79951704255
-
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis
-
Iacobellis A., Perri F., Valvano M.R., et al. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011, 9:249-253.
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 249-253
-
-
Iacobellis, A.1
Perri, F.2
Valvano, M.R.3
-
40
-
-
84920990853
-
Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study
-
Boston (MA), November 7-11
-
Flamm SL, Everson GT, Charlton MR, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Program and abstracts of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases. Boston (MA), November 7-11, 2014. Abstract 239.
-
(2014)
Program and abstracts of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases
-
-
Flamm, S.L.1
Everson, G.T.2
Charlton, M.R.3
-
42
-
-
84943583893
-
Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study
-
Vienna (Austria), April 22-26
-
Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract L08. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
-
(2015)
Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
-
-
Poordad, F.1
Schiff, E.R.2
Vierling, J.M.3
-
43
-
-
84939269033
-
A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2
-
Vienna (Austria), April 22-26
-
Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP04. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
-
(2015)
Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
-
-
Lawitz, E.1
Matusow, G.2
DeJesus, E.3
-
44
-
-
84973461613
-
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real world experience from HCV-TARGET
-
Vienna (Austria), April 22-26
-
Saxena V, Koraishy FM, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real world experience from HCV-TARGET. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP08. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
-
(2015)
Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
-
-
Saxena, V.1
Koraishy, F.M.2
Sise, M.3
-
45
-
-
84929600780
-
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
-
Wyles D., Pockros P., Morelli G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015, 61(6):1793-1797.
-
(2015)
Hepatology
, vol.61
, Issue.6
, pp. 1793-1797
-
-
Wyles, D.1
Pockros, P.2
Morelli, G.3
-
46
-
-
84999899643
-
Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
-
Vienna (Austria), April 22-26
-
Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract O005. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
-
(2015)
Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
-
-
Lawitz, E.1
Flamm, S.2
Yang, J.C.3
-
47
-
-
84939254831
-
Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
-
Forns X., Gordon S.C., Zuckerman E., et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015, 10.1016/j.jhep.2015.04.009.
-
(2015)
J Hepatol
-
-
Forns, X.1
Gordon, S.C.2
Zuckerman, E.3
-
48
-
-
84896700801
-
Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions
-
Ravi S., Nasiri-Toosi M., Karimzadeh I., et al. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opin Drug Saf 2014, 13:277-286.
-
(2014)
Expert Opin Drug Saf
, vol.13
, pp. 277-286
-
-
Ravi, S.1
Nasiri-Toosi, M.2
Karimzadeh, I.3
-
49
-
-
84893819990
-
What is the future of ribavirin therapy for hepatitis C?
-
Koh C., Liang T.J. What is the future of ribavirin therapy for hepatitis C?. Antivir Res 2014, 104:34-39.
-
(2014)
Antivir Res
, vol.104
, pp. 34-39
-
-
Koh, C.1
Liang, T.J.2
-
50
-
-
84947617637
-
-
[package insert]. Whitehouse station (NJ): Merck & Co, Inc
-
Rebetol [package insert]. Whitehouse station (NJ): Merck & Co, Inc; 2014.
-
(2014)
-
-
-
51
-
-
84925424553
-
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patient with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
-
Lawitz E., Gane E., Pearlman B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patient with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014, 385(9973):1075-1086. Available at:. http://www.jwatch.org/na36381/2014/12/04/promising-all-oral-hcv-regimen-difficult-treat-groups#sthash.upvkVlyJ.dpuf.
-
(2014)
Lancet
, vol.385
, Issue.9973
, pp. 1075-1086
-
-
Lawitz, E.1
Gane, E.2
Pearlman, B.3
-
52
-
-
84937064772
-
Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial
-
Zeuzem S., Ghalib R., Reddy K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015, 10.7326/M15-0785.
-
(2015)
Ann Intern Med
-
-
Zeuzem, S.1
Ghalib, R.2
Reddy, K.R.3
-
53
-
-
84929207643
-
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
-
Poordad F., Sievert W., Mollison L., UNITY-1 Study Group, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015, 313:1728-1735.
-
(2015)
JAMA
, vol.313
, pp. 1728-1735
-
-
Poordad, F.1
Sievert, W.2
Mollison, L.3
UNITY-1 Study, Group4
-
54
-
-
84929208843
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
-
Muir A.J., Poordad F., Lalezari J., et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015, 313:1736-1744.
-
(2015)
JAMA
, vol.313
, pp. 1736-1744
-
-
Muir, A.J.1
Poordad, F.2
Lalezari, J.3
-
55
-
-
84925607745
-
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
-
Kohli A., Osinusi A., Sims Z., et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015, 385:1107-1113.
-
(2015)
Lancet
, vol.385
, pp. 1107-1113
-
-
Kohli, A.1
Osinusi, A.2
Sims, Z.3
-
56
-
-
84971496437
-
Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype 1 patients with and without cirrhosis
-
Vienna (Austria), April 22-26
-
Gane EJ, Hyland RH, Tang Y, et al. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype 1 patients with and without cirrhosis. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP03. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
-
(2015)
Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
-
-
Gane, E.J.1
Hyland, R.H.2
Tang, Y.3
-
57
-
-
84891543215
-
A small-molecule inhibitor of hepatitis C virus infectivity
-
Bush C.O., Pokrovskii M.V., Saito R., et al. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother 2014, 58(1):386-396.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.1
, pp. 386-396
-
-
Bush, C.O.1
Pokrovskii, M.V.2
Saito, R.3
|